Please use this identifier to cite or link to this item:
|Title:||Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.||Authors:||Forsyth, Cecily J ;Agarwal, R.;Blombery, P.;McBean, M.;Jones, K.;Fellowes, A.;Doig, K.;Westerman, D.A.||Affliation:||Central Coast Local Health District
|Issue Date:||Feb-2017||Source:||96(5):725-732||Journal title:||Annals of Hematology||Department:||Haematology||Abstract:||Mutations in CALR have recently been detected in JAK2-negative myeloproliferative neoplasms (MPNs) and are key pathological drivers in these diseases. CALR-mutated MPNs are shown to have numerous clinicopathological differences to JAK2-mutated MPNs. The basis of these differences is poorly understood. It is unknown whether these differences result directly from any differences in intracellular signalling abnormalities induced by JAK2/CALR mutations or whether they relate to other phenomena such as a differing spectrum of genetic lesions between the two groups. We aimed to review the clinicopathological and molecular features of CALR- and JAK2-mutated MPNs from samples referred for diagnostic testing using a custom-designed targeted next-generation sequencing (NGS) panel. Eighty-nine CALR-mutated cases were compared with 70 JAK2-mutated cases. CALR-mutated MPNs showed higher platelet counts and a female predominance as compared to JAK2-mutated MPNs in our cohort. We have also observed differences between CALR mutation subtypes in terms of disease phenotype, mutational frequency and allelic burden. Type 1 CALR mutations were found to be more common in myelofibrosis, associated with a higher frequency and number of additional mutations and a higher mutant allelic burden as compared to type 2 CALR mutations. Despite these biological differences, our molecular characterisation suggests that CALR- and JAK2-mutated MPNs are broadly similar in terms of the quantity, frequency and spectrum of co-occurring mutations and therefore observed biological differences are likely to not be heavily influenced by the nature and quantity of co-mutated genes.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/996||DOI:||10.1007/s00277-017-2937-6||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/28161773||ISSN:||0939-5555||Publicaton type:||Journal Article||Keywords:||Hematology|
|Appears in Collections:||Haematology|
Show full item record
checked on Feb 3, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.